-- CANADA RESEARCH ROUNDUP-Dragonwave, Precision Drilling, Ensign Energy Services  
-- 
-- Wed May 21, 2014 07:26AM EDT
-- None



May 21 (Reuters) - Securities analysts revised their ratings and price targets on several Canadian companies, including Endeavour Mining, Ensign Energy Services and Valeant Pharmaceuticals, on Wednesday.

HIGHLIGHTS  * Endeavour Mining <EDV.TO>: BMO starts with market perform rating* Ensign Energy Services <ESI.TO>: Barclays cuts to underweight from equal weight * Precision Drilling <PD.TO>: Barclays raises to overweight from equal weight * Valeant Pharmaceuticals International <VRX.N>: CIBC starts with sector outperformer rating * Semafo Inc <SMF.TO>, Asanko Gold Inc <AKG.TO>: Raymond James starts with outperform rating  Following is a summary of research actions on Canadian companies reported by Reuters on Wednesday. Stock entries are in alphabetical order. * Asanko Gold Inc <AKG.TO>: Raymond James starts with outperform rating; target price C$3.75 * CI Financial Corp <CIX.TO>: RBC raises to outperform from sector perform  * Dragonwave <DWI.TO>: CIBC cuts price target to C$1 from C$2; rating sector underperformer  * Endeavour Mining <EDV.TO>: BMO starts with market perform rating * Ensign Energy Services <ESI.TO>: Barclays cuts to underweight from equal weight * Ensign Energy Services <ESI.TO>: Barclays cuts target price to C$14 from C$17 * LoneStar West Inc <LSI.V>: NBF raises target price to C$4.60 from C$4.30; outperform  * Mosaic Capital <M.V>: Raymond James raises target to C$13.75 from C$12.50; outperform  * Petromanas Energy Inc <PMI.V>: Haywood raises price target by C$0.10 to C$0.45; rating buy * Precision Drilling <PD.TO>: Barclays raises to overweight from equal weight * Precision Drilling <PD.TO>: Barclays raises target price to C$17 from C$15  * Semafo Inc <SMF.TO>: Raymond James starts with outperform rating; target price C$4.75  * Strongco <SQP.TO>: Canaccord Genuity raises target price to C$6 from C$5.50; rating buy  * Valeant Pharmaceuticals International <VRX.N>: CIBC starts with sector outperformer rating * Valeant Pharmaceuticals International <VRX.N>: CIBC starts with price target $160